愷英網絡(002517.SZ):部分董事、高管已完成增持計劃 累計增持1778.4萬股
格隆匯11月9日丨愷英網絡(002517.SZ)公佈,公司於2021年11月9日接到公司董事長金鋒、副董事長兼副總經理沈軍、董事兼總經理陳永聰通知,金鋒、沈軍、陳永聰已完成股份增持計劃。
自2021年8月31日至目前,金鋒累計通過集中競價方式增持公司股份1428.4萬股,佔公司總股本的0.66%,累計增持金額約5740.24萬元;沈軍累計通過司法拍賣方式增持公司股份175萬股,佔公司總股本的0.08%,累計增持金額約634.2萬元;陳永聰累計通過司法拍賣方式增持公司股份175萬股,佔公司總股本的0.08%,累計增持金額約634.20萬元,此次增持計劃已完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.